Asterias stem cell
therapy shows promise in spinal cord paralysis: U.S.
Send a link to a friend
[September 14, 2016]
By Bill Berkrot
NEW YORK (Reuters) - An experimental stem
cell therapy developed by Asterias Biotherapeutics restored some
movement to patients paralyzed by recent spinal cord injuries, according
to interim data from a small study being presented on Wednesday.
One of the five patients in the trial regained use of both arms and
hands, and is now able to feed himself, send texts on a phone and
operate a wheelchair, the Fremont, California-based company said.
Three months after the cells were implanted, the study met its
efficacy goal of two patients regaining return of two motor levels
of functioning on at least one side of their body, the company said.
All five people in the study have experienced some upper extremity
improvement so far, Asterias said.
Each motor level function measurement correlates with a reduction in
the assistance and care a paralyzed patient might require. A
two-level improvement can mean a patient is able to live more
The cells are injected by a neurosurgeon directly into the site of
the spinal cord damage within two to four weeks of injury, before
scar tissue forms. The hope is that they can help restore signals
from the brain through the spinal cord to the outer extremities.
Stem cells are able to transform into various other types of cells
in the body, and scientists have been working for years to try to
harness their unique capabilities to combat various medical
conditions, including paralysis and heart failure.
"I am very encouraged by this first look at efficacy data in
complete cervical spinal cord patients," Dr. Shekar Kurpad, a trial
researcher and director of the Spinal Cord Injury Center at the
Medical College of Wisconsin, said in a statement.
The company had not expected to reach the efficacy goal before six
to 12 months after implantation of the 10 million embryonic stem
cells dubbed AST-OPC1, Asterias Chief Executive Stephen Cartt said.
[to top of second column]
"We came out early with the data because it was so compelling. We
were expecting to wait until January," Cartt said in a telephone
interview, acknowledging that the work is still in the early stages
and that it is a very small study.
The interim results were presented at the International Spinal Cord
Society meeting in Vienna, Austria.
There were no reported serious adverse side effects related to
AST-OPC1 or the injection procedure, Asterias said.
The company has secured regulatory approval to double the dose to 20
million cells in future studies.
The five patients will be followed and assessed for 12 months.
"It's certainly our hope that we see at least that these gains are
maintained, and we hope to see continuing improvement," Cartt said.
(Reporting by Bill Berkrot; Editing by Will Dunham)
[© 2016 Thomson Reuters. All rights
Copyright 2016 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.